Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS) in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs)

被引：0
|
作者：
Kunstfeld, R. [1 ]
Zloty, D. [2 ]
Tang, J. [3 ]
Basset-Seguin, N. [4 ]
Bissonnette, R. [5 ]
Grob, J. -J. [6 ]
Maher, I. [7 ]
Bergstrom, D. [8 ]
Gilberg, F. [8 ]
Dreno, B. [9 ]
Rogers, G. [10 ]
Schadendorf, D. [11 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Univ British Columbia, Vancouver, BC, Canada
[3] Stanford Univ, La Jolla, CA USA
[4] Hop St Louis, Paris, France
[5] Innovaderm Res Inc, Montreal, PQ, Canada
[6] Aix Marseille Univ, Hop Timone, APHM, Marseille, France
[7] St Louis Univ, Sch Med, St Louis, MO USA
[8] Hoffman La Roche Ltd, Basel, Switzerland
[9] Univ Nantes, Nantes, France
[10] Tufts Univ, Sch Med, Boston, MA 02111 USA
[11] Univ Klinikum Essen, Essen, Germany
来源：
MELANOMA RESEARCH | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P134
引用
收藏
页码：E78 / E78
页数：1
相关论文
共 49 条
  • [1] Mikie: A randomized, double-blinded, regimen controlled, phase 2 study to assess the efficacy and safety of two different vismodegib (VISMO) regimens in patients (pts) with multiple basal cell carcinomas (BCCs).
    Rogers, Gary
    Kunstfeld, Rainer
    Schadendorf, Dirk
    Hauschild, Axel
    Maher, Ian
    Zloty, David
    Labeille, Bruno
    Grob, Jean Jacques
    Puig, Susana
    Bergstrom, Daniel
    Gilberg, Frank
    Dreno, Brigitte
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Evaluation of the pharmacokinetic (PK) profile of vismodegib (VISMO) in patients (pts) with multiple basal cell carcinomas (BCCs) across two intermittent treatment regimens in the MIKIE study
    Schadendorf, D.
    Hauschild, A.
    Fosko, S.
    Zloty, D.
    Labeille, B.
    Grob, J. J.
    Puig, S.
    Makrutzki, M.
    Templeton, I.
    Rogers, G.
    Dreno, B.
    Kunstfeld, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in patients (pts) with multiple basal cell Carcinomas (BCCs)
    Dreno, B.
    Hauschild, A.
    Maher, I.
    Zloty, D.
    Labeille, B.
    Grob, J. -J.
    Puig, S.
    Karagiannis, T.
    Gilberg, F.
    Schadendorf, D.
    Kunstfeld, R.
    Rogers, G.
    MELANOMA RESEARCH, 2016, 26 : E72 - E72
  • [4] Long-term follow-up from MIKIE: A randomized, double-blind, phase 2 study to assess the efficacy and safety of two intermittent vismodegib regimens in patients with multiple Basal Cell Carcinomas (BCCs)
    Kunstfeld, R.
    Rogers, G.
    Dreno, B.
    Hauschild, A.
    Fosko, S.
    Zloty, D.
    Labeille, B.
    Grob, J. -J.
    Puig, S.
    Makrutzki, M.
    Gilberg, F.
    Schadendorf, D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 41 - 41
  • [5] Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, long-term follow-up from the randomized, phase 2 study to assess the efficacy and safety of two intermittent vismodegib regimens in patients with multiple Basal Cell Carcinomas (BCCs)
    Schadendorf, D.
    Hauschild, A.
    Fosko, S.
    Zloty, D.
    Labeille, B.
    Grob, J. -J.
    Puig, S.
    Makrutzki, M.
    Gilberg, F.
    Dreno, B.
    Rogers, G.
    Kunstfeld, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 41 - 41
  • [6] MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
    Kunstfeld, Rainer
    Hauschild, Axel
    Zloty, David
    Rogers, Gary
    Dreno, Brigitte
    Mitchell, Lada
    Stamawski, Michel
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials
    Anne Lynn S. Chang
    Sarah T. Arron
    Michael R. Migden
    James A. Solomon
    Simon Yoo
    Bann-Mo Day
    Edward F. McKenna
    Aleksandar Sekulic
    Orphanet Journal of Rare Diseases, 11
  • [8] Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials
    Chang, Anne Lynn S.
    Arron, Sarah T.
    Migden, Michael R.
    Solomon, James A.
    Yoo, Simon
    Day, Bann-Mo
    McKenna, Edward F.
    Sekulic, Aleksandar
    ORPHANET JOURNAL OF RARE DISEASES, 2016, 11
  • [9] Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome
    Weiss, Glen J.
    Tibes, Raoul
    Blaydorn, Lisa
    Jameson, Gayle
    Downhour, Molly
    White, Erica
    Caro, Ivor
    Von Hoff, Daniel D.
    DERMATOLOGY REPORTS, 2011, 3 (03) : 125 - 127
  • [10] Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study
    Schadendorf, D.
    Hauschild, A.
    Fosko, S.
    Zloty, D.
    Labeille, B.
    Grob, J. -J.
    Puig, S.
    Makrutzki, M.
    Gilberg, F.
    Hong, A.
    Dreno, B.
    Rogers, G.
    Kunstfeld, R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (09) : E526 - E529
12345